Wnt5b-induced PCP/JNK Activation Promotes PD-L1 Expression and the Malignant Phenotype of Non-small Cell Lung Cancer

Guangping Wu  
China Medical University

Yuan Luo  
China Medical University

Yusai Xie  
China Medical University

Yang Han  
China Medical University

Di Zhang  
China Medical University

Qiang Han  
China Medical University

Xinran Zhao  
China Medical University

Ye Qin  
China Medical University

Qingchang Li  
China Medical University

Enhua Wang  
China Medical University

Huanyu Zhao (✉️ zhaohy@cmu.edu.cn)  
Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China  
https://orcid.org/0000-0003-4041-5617

Research

Keywords: Wnt5b, Dvl-3, JNK, PD-L1, non-small cell lung cancer

Posted Date: September 14th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-74120/v1
Title page

Title

Wnt5b-induced PCP/JNK activation promotes PD-L1 expression and the malignant phenotype of non-small cell lung cancer

Authors

Guangping Wu¹, Yuan Luo¹, Yusai Xie¹, Yang Han¹, Di Zhang¹, Qiang Han¹, Xinran Zhao¹, Ye Qin¹, Qingchang Li¹, Enhua Wang¹, Huanyu Zhao¹*

¹ Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China

* Corresponding author: Huanyu Zhao, Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University; postal address: No. 155 Nanjing North Street, Heping District, Shenyang, Liaoning, 110001, China; telephone and fax numbers: 86-24-83282177; email: zhaohy@cmu.edu.cn
Abstract

**Background:** Wnt5b is noncanonical Wnt ligand, and programmed-death ligand 1 (PD-L1) is a targeted agent for immunotherapy, but the mechanism by which Wnt5b regulates PD-L1 expression in non-small cell lung cancer (NSCLC) is unclear.

**Methods:** Wnt5b and PD-L1 expressions were detected in NSCLC specimens by immunohistochemistry. The interrelationship connecting Wnt5b with PD-L1 was verified using dual-luciferase assay, immunofluorescence, coimmunoprecipitation, western blot, real-time PCR and xenograft tumor model.

**Results:** Wnt5b and PD-L1 expressions were positively correlated in NSCLC specimens. Five-year survival time in the group with their coexpression was significantly lower than that without coexpression. Under the effect of Wnt5b, Frizzled-3 (Fzd3) initiated Dishevelde-3 (Dvl-3) membrane recruitment via DEP domain by Dvl-3 phosphorylation, contributing to activate PCP/JNK signaling through the small GTPase Rac1, and then upregulate PD-L1 expression and promote the malignant phenotype of NSCLC in vivo and in vitro. After PD-L1 antibody treatment, Wnt5b induced tumor growth was inhibited significantly in xenograft tumor model.

**Conclusion:** We demonstrate a new signal transduction pathway: Wnt5b initiates Dvl-3 membrane recruitment via DEP domain by Fzd3 so as to promote Rac1–PCP/JNK–PD-L1 pathway, which provides a potential target for clinical intervention and immunotherapy in lung cancer.
**Keywords:** Wnt5b, Dvl-3, JNK, PD-L1, non-small cell lung cancer

**Background**

Lung cancer is the leading cause of death of malignant tumor in the world. The invasion and metastasis are most likely to occur in the early stage, leading to the poor prognosis of the patient [1, 2]. Therefore, seeking for new therapeutic target is helpful to improve the prognosis and treatment of this disease.

Wnt pathway is important for tumorigenesis, including canonical Wnt/β-catenin pathway and noncanonical Wnt pathway. Wnt/PCP (planar cell polarity) belongs to noncanonical Wnt pathway, contributing to tumor invasion and metastasis [3]. Wnt ligand is a highly conserved secreted glycoprotein including 19 members, and Wnt5b belongs to noncanonical Wnt ligand. It regulates Wnt/PCP pathway [4]. Wnt5b is associated with the malignant phenotype of lung adenocarcinoma [5, 6]. However, the molecular mechanism by which Wnt5b takes part in PCP pathway in NSCLC is still unclear.

Recently, the research on tumor microenvironment has become a hot topic, especially PD-1/PD-L1 (programmed cell death protein 1; programmed death-ligand 1) immune checkpoints [7]. PD-L1 expressed by cancer cells acts as an inhibitor of human T cell responses [8]. PD-1 is able to dampen autoimmunity in the peripheral effector phase of T-cell activation. The interaction of cancer cells expressing PD-L1 with T cells expressing PD-1 enables cancer cells to obtain immune escape [9]. So the regulatory mechanisms of PD-L1 expression in cancer cells are worth researching. PD-L1
expression in triple-negative breast cancer is regulated by Wnt signaling [10]. However, the regulatory mechanisms of PD-L1 expression by Wnt signaling in NSCLC has not been reported.

Dishevelled (Dvl, consists of Dvl-1, Dvl-2 and Dvl-3) is a scaffold protein in Wnt pathway [11, 12], including three domains: DIX, DEP and PDZ. Dvl-3 affect the malignant phenotype of NSCLC mainly through noncanonical Wnt pathway [13, 14]. As a major signaling cassette of the mitogen-activated protein kinase (MAPK), the c-Jun N-terminal kinase (JNK) takes part in Wnt/PCP signaling [15-17]. Previous study confirmed that Dvl-3 could activate JNK in NSCLC [13], and also JNK activation is crucial for PD-L1 regulation in ovarian cancer cells [18]. Frizzled (Fzd) family belongs to seven transmembrane receptors, including ten isoforms (Fzd1-10). It binds to Wnt ligand and then interacts with Dvl to promote the Dvl phosphorylation for downstream cascade reaction [19, 20].

In summarize, we speculate that Wnt5b may impact one or more domains of Dvl-3 via a specific Fzd isoform so as to active Wnt/PCP signaling and regulate PD-L1 expression in NSCLC. In this work, we examined the Wnt5b and PD-L1 expression in NSCLC specimens. NSCLC xenograft murine models induced by Wnt5b combination with an anti-mouse PD-L1 antibody were established to explore the efficacy of anti-PD-L1 therapy in NSCLC. And we also elucidated the mechanism by which Wnt5b regulates PD-L1 expression involved in Wnt/PCP pathway.
Methods

Patients and specimens

We collected 137 NSCLC specimens (average age: 60 years). From 2004 to 2014, these patients underwent surgery at the First Affiliated Hospital of China Medical University, and none of them received radiotherapy or chemotherapy before resection. Written informed consent was obtained from them. Work procedures were approved by the Institute Research Ethics Committee (No. 2016 [LS] 014, China Medical University). We obtained tumor specimens during surgical resection. Histologic subtype is based on the 2015 classification criteria to lung cancer of the World Health Organization [21]; tumor stage is based on the 2010 International Union of cancer TNM staging standards [22]. Complete follow-up data was available for all the patients. Clinicopathological information is in Table 1.

We also collected 22 fresh paired carcinoma and adjacent noncancerous tissues, which were immediately stored at −70°C for mRNA and protein extraction.

Immunohistochemistry

Experimental procedures were performed as previous studies [13]. We incubated tissue sections with Wnt5b antibody (1:50, Abcam, ab94914). The intensity of Wnt5b staining was scored as following: 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (strong staining). The percentage scores of Wnt5b staining were assigned as following: 1 (1%–25%), 2 (26%–50%), 3 (51%–75%), and 4 (76%–100%). The above two scores were multiplied to give a final score: 0 to 12. The
scores of ≥4 were defined as Wnt5b overexpression (positive expression); the scores between 1 and 4 were defined as weak expression (negative expression). The informations of PD-L1 staining were in Supplemental materials and methods.

PD-L1 staining was performed by using the Dako automated staining platform according to the manufacturer’s standard steps (Dako 22C3 PharmDx Assay, Dako Autostainer Link 48, Agilent, Santa Clara, CA, USA). We determined the PD-L1 expression in tumor cells by using Tumor Proportion Score (TPS). TPS was calculated as the percentage of at least 100 viable tumor cells with complete or partial membrane staining. The percentage of ≥50% was defined as PD-L1 positive expression; and that of <50% was defined as PD-L1 positive expression.

Cell culture, reagents and plasmid reconstruction

HBE cell was from the American Type Culture Collection (ATCC) (Manassas, VA, USA), and NSCLC cell lines (A549, SPC, H157, H460, LTE) were from the Shanghai Cell Bank (Shanghai, China). They were authenticated by short tandem repeat DNA profiling. We cultured cells according to the instructions of the ATCC.

siRNA-Wnt5b (sc-155357), siRNA-Fzd1 (sc-39977), siRNA-Fzd2 (sc-39979), siRNA-Fzd3 (sc-39981), siRNA-Fzd4 (sc-39983), siRNA-Fzd5 (sc-39985), siRNA-Fzd6 (sc-39987), siRNA-Fzd7 (sc-39990), siRNA-Fzd8 (sc-39992), siRNA-Fzd9 (sc-39994), siRNA-Fzd10 (sc-39996) and siRNA-negative control (sc-37007) were purchased from Santa Cruz Biotechnology Inc. pGPU6-Wnt5b-shRNA and pGPU6-NC-shRNA were purchased from GenePharma
(Shanghai, China). ML141 (a cdc42 inhibitor) and NSC23766 (a Rac1 inhibitor) were purchased from R&D Systems (Minneapolis, MN, USA). SP600125 (JNK inhibitor) were purchased from Merck Millipore (Bedford, MA).

pCMV6-AC-GFP-Wnt5b (RG200847) was purchased from Origene (Rockville, MD, USA). The pMyc-cyto and pMyc-cyto-Dvl-3 were provided by Dr. Jun Liu (Department of Chemistry, The Scripps Research Institute, La Jolla, CA).

The mutant Dvl-3 plasmids include the deletion of the DIX domain of Dvl-3 (myc-ΔDIX-Dvl-3), the deletion of the PDZ domain of Dvl-3 (myc-ΔPDZ-Dvl-3), the deletion of the DEP domain of Dvl-3 (myc-ΔDEP-Dvl-3) and the deletion of the DEP and PDZ domains of Dvl-3(myc-ΔDEP+PDZ-Dvl-3). They were produced by RiboBio (Guangzhou, China).

**RNA extraction and Real-time PCR**

We used PrimeScript™ RT reagent Kit (TaKaRa, Dalian, China) to perform Real-time PCR according to manufacturer’s instruction. The experimental steps are conducted as the previous study [13]. β-actin was normalized reference. The sequences of primers in this research were shown in Table S1.

**Western blot and immunoprecipitation**

The experimental steps are conducted as the previous study [13]. We separated the membrane and cytosolic proteins by using Membrane and Cytosol Protein Extraction kit according to manufacturer’s instruction (Beyotime Institute of Biotechnology,
Haimen, China). Detailed information of the antibodies is in Table S2.

**Immunofluorescence staining**

The experimental steps are conducted as the previous study [13]. After being treated with corresponding factors, the cell line was incubated overnight with an antibody against myc (1:50).

**Dual-luciferase assay**

We plated cells in 24-well plate. After incubation for 24 h, we transfected the mixture of 100 ng ATF2 (Wnt/PCP signalling, Promega, Madison, WI), or 100 ng TopFlash and FopFlash (Addgene, Cambridge, MA, USA), and 10 ng Renilla (Promega) according to the instructions of Lipofectamine 2000 (Invitrogen, Carlsbad, USA). Cells were treated with the indicated factors in addition to transfection of corresponding luciferase reporter gene vector. After incubation for 48 h, dual-luciferase assay system (Promega) was performed to measure the luciferase activity according to the instructions of manufacturer. We used TopFlash/FopFlash to measure β-catenin-dependent Wnt activity and ATF2 luciferase to measure Wnt/PCP activity. The values of various luciferase activities were normalized with Renilla activity. We repeated all the experiments at least three times.

**Transwell assay**
Transwell membranes (8 µm pore polycarbonate membrane, in 24-well plates) were used. We used Matrigel (BD Bioscience) on the upper surface of the membrane in every well. In the upper chamber, we cultured the cells (3 × 10^5 cells) in 100 µL serum-free medium; in the lower chamber, we added the medium containing 10% FBS. After incubation for 20 h, we stained the cells with hematoxylin (Sigma). Ten fields (400 × magnification) of each filter were randomly selected under microscope for counting the number of the invaded cells.

**Cell scratch experiment**

We seeded cells in six-well plates. After being treated with corresponding factors, the well was scratched by a 100 µL pipette tip. At 1 h and 24 h time points, we measured the scratch width under the microscope at three separated sites. The experiments were performed for three times.

**Cdc42 and Rac1 GTPase Activation Assay**

Rac1/cdc42 activation assay kit (Sigma-Aldrich, Deisenhofen, Germany) was used in this study according to manufacturer’s instructions. After the pulldown reaction with GST-PAK-PBD (p21 binding domain of p21 activated kinase) beads, the precipitated proteins binding to the beads were performed to take immunoblotting assay with Rac1/cdc42 monoclonal antibody. We aslo determined the total amount of Rac1 or cdc42 by Western blot using total cell lysates.
Colony formation and MTT assays

The experimental steps are conducted as the previous study [13]. The experiments were performed for three times.

Transplantation of tumor cells into nude mice

The mice were treated in accordance with the experimental animal ethics guidelines established by China Medical University. The Institutional Animal Research Committee of China Medical University approved this study. We purchased specific pathogen-free (SPF) BALB/c nude mice (four-week-old; female; 17.54 ± 0.68 g) from Charles River (Beijing, China). In animal center of our university, we housed the mice in a controlled room with free access to food and water available. The condition of the room is 12 h light/dark cycle, a temperature of 24 ± 2°C and (55 ± 10)% relative humidity. There were sterilised wood shavings in the cages of the mice. Before surgical treatment, the mice were anesthetized with by intraperitoneal injection of Pentobarbital Sodium (40mg/kg; Sigma Aldrich, St.Louis, USA). We conducted the experimental procedures in the SPF laboratory during light phases.

NSCLC cells (Wnt5b expression plasmid-transfected A549 cells; Wnt5b-shRNA-transfected SPC and H157 cells; corresponding vector-transfected control cells) suspended in 0.2 ml PBS were intravenously inoculated to the tail vein (2 × 10^6 cells per mouse) or subcutaneously inoculated into the right flank (5 × 10^6 cells per mouse). Volume calculation formula for calculating tumour volume: length x width^2 x 0.5. Animals were randomized in the 2 following treatment groups (n=5 in
each group): Wnt5b expression plasmid-transfection or Wnt5b-shRNA-transfection, corresponding vector-transfection. After inoculation for 6 weeks, these nude mice were killed by cervical dislocation and then autopsied for collecting tumours and lungs. Dissected tissue and organs were fixed in 4% formaldehyde and then embedded in paraffin. We cut them into 4-μm-thick sections and stained them with hematoxylin to observe under microscope.

For detecting the effect of PD-L1, we subcutaneously inoculated NSCLC cells into the right flank as above. Animals were randomized in the 2 groups (n=5 in each group). When tumor volume reached to 90–100 mm$^3$, mice were treated twice a week (10 mg/kg) for 3 weeks days as following: anti-mouse PD-L1 antibody (Bioxcell) in Group 1; IgG2b antibody (New Hampshire, USA, Bioxcell) in Group 2. The antibody was executed by intraperitoneal injection. Then whole tumor was removed for study.

Statistical analysis

SPSS 17.0 was used for all analyses in this study. Chi-squared test was used to calculate corresponding correlations. Kaplan–Meier analysis was used to demonstrate the survival time among different groups of patients. A two-tailed P < 0.05 was considered to be statistically significant.

Results

Wnt5b and PD-L1 corexpression in NSCLC is correlated with poor prognosis

Wnt5b expression in 137 NSCLC samples and 36 paired non-cancerous samples was
detected by immunohistochemistry. Negative Wnt5b expression was in the normal bronchial and alveolar epithelial cells; in contrast, 62.8% of NSCLC tissues (86/137) had positive Wnt5b expression (Fig. 1a, Table 1).

Additionally, we evaluated the Wnt5b expression in 22 fresh NSCLC tissues. Wnt5b mRNA and protein expressions were higher in NSCLC tissues than that in matched paracancerous tissues (22/22; Fig. 1b and Fig. S1a). Compare with the normal bronchial epithelial cell line HBE, Wnt5b had high expression in NSCLC cells (Fig. 1c).

Wnt5b overexpression was significantly associated with high TNM stage and lymph node metastasis in NSCLC (Table 1, P<0.05). Kaplan–Meier survival analysis revealed that the overall survival for patients with Wnt5b overexpression was significantly shorter than that without Wnt5b overexpression (P<0.05; Fig. 1d).

PD-L1 expression in NSCLC tissues was significantly higher than that in paired normal tissues (Fig. 1a); Wnt5b and PD-L1 expressions were positively correlated in NSCLC tissues (r = 0.198, P<0.05, Table 1). The overall survival for patients with Wnt5b and PD-L1 coexpression was significantly shorter than that without coexpression (P<0.05; Fig. 1e).

**Wnt5b promotes the malignant phenotype of NSCLC cells**

To verify the effect of Wnt5b on the biological function of NSCLC cells, we transfected A549 cell (low Wnt5b expression) with Wnt5b expression plasmid. Wnt5b overexpression promoted the cell invasiveness, colony formation, proliferation and
migration. And Wnt5b knockdown (siRNA-Wnt5b) inhibited cell invasiveness, colony formation, proliferation and migration in SPC and H157 cells (Fig. 2a–h; Fig. S1b and S2a–d).

To assess the effect of Wnt5b on the tumorigenesis, NSCLC cells were intravenously injected via the tail vein or subcutaneously injected into nude mice. Compared with the control group (CTL), the weight and volume of subcutaneously injected tumours were increased in the Wnt5b overexpression group, and Wnt5b knockdown (shRNA-Wnt5b) had the opposite effect (A549: CTL versus Wnt5b; weight, 0.52±0.05 g versus 1.31±0.11 g; volume, 0.54±0.08 cm³ versus 1.43±0.13 cm³. SPC: shNC versus shRNA-Wnt5b; weight, 0.99±0.11 g versus 0.59±0.12 g; volume, 1.18±0.13 cm³ versus 0.59±0.06 cm³; P<0.05) (Fig. 2i–n; Fig. S2e–g). Compared with the control group, Wnt5b overexpression increased intrapulmonary metastasis formation, and Wnt5b knockdown had the opposite effect (lung metastasis rate: A549, CTL versus Wnt5b, 1/4 versus 4/4; SPC, shNC versus shRNA-Wnt5b, 4/4 versus 1/4) (Fig. 2o–r and Fig. S2h–i). Therefore, Wnt5b might function as a positive regulator of the progression of NSCLC in vitro and in vivo.

**Wnt5b activates the Wnt/PCP signaling in NSCLC cells**

Wnt5b is involved in PCP/JNK signaling [23]. Herein, we carried out luciferase reporter assays with an ATF2 reporter system, which is a robust readout for JNK signaling in Xenopus embryos [24]. Wnt5b overexpression strongly activated the ATF2 luciferase reporter, whereas Wnt5b knockdown had the opposite effect (Fig. 3a).
And Wnt5b had no effect on canonical Wnt signaling (TopFlash/FopFlash for Wnt/β-catenin signaling, Fig. S3a).

Next we detected the key factors in the Wnt/PCP pathway. Small GTPases Rac1 and cdc42 are involved in Wnt/PCP signaling [25, 26]. Wnt5b overexpression significantly upregulated the protein levels of Rac1 and cdc42, and Wnt5b knockdown had the opposite effect (Fig. 3b). The mRNA expressions of Rac1 and cdc42 were also positively regulated by Wnt5b (Fig. S3b). And Wnt5b had no effect on target genes (c-myc and cyclin D1) of canonical Wnt signaling (Fig. 3b and Fig. S3c). Above results confirm that Wnt5b activates Wnt/PCP signaling.

**Wnt5b promotes Dvl-3 phosphorylation through Fzd3 in NSCLC cells**

Dvl-1 and Dvl-3 affect malignant phenotype of NSCLC through different Wnt pathway. Herein, Wnt5b could enhance Dvl-3 phosphorylation, but had no influence on Dvl-1 phosphorylation (Fig. 3b). Dvl-3 could activate JNK signaling to promote the malignant phenotype of NSCLC [13]. This has great significance for Wnt/PCP signaling [17, 27].

The transmembrane receptor Fzd binds to Wnt ligand, and then transduces downstream signals to the nucleus via Dvl [28]. Wnt5b is a noncanonical Wnt ligand, and Dvl-3 plays an important role in noncanonical Wnt pathway [13]. It reminds us that there is complex interaction among Wnt5b, Fzd and Dvl-3. Coimmunoprecipitation assay confirmed this (Fig. 3c).

Fzd includes ten isoforms. Fzd3 and Fzd6 are involved in Wnt/PCP pathway [29, 30].
To verify the effect of Fzds on Wnt5b induced Dvl-3 phosphorylation, we cotransfected siRNA-Fzd1-10 with Wnt5b expression plasmid (GFP-Wnt5b) to A549 cell. Fzd3 knockdown significantly inhibited the Wnt5b induced Dvl-3 phosphorylation, as well as the activation of the ATF2 reporter (Fig. 3d, e). And other isoforms had not this effect (Fig. S4–5). Coimmunoprecipitation assay confirmed that Wnt5b interacted with Fzd3 and Dvl-3, but this interaction was significantly weakened by siRNA-Fzd3 (Fig. 3f–h and Fig. S6). So Wnt5b promoted Dvl-3 phosphorylation through Fzd3.

Dvl-3 DEP domain is necessary for Wnt5b-mediated Dvl-3 phosphorylation through Fzd3 on cell membrane and the malignant phenotype of NSCLC cell induced by Wnt5b

Dvl includes three domains: DIX, DEP and PDZ. Different domains affect different Wnt pathways [31, 32]. Binding of Fzd through Dvl DEP domain is necessary for Dvl membrane recruitment upon Wnt stimulation and the propagation of downstream signals [33-35]. Herein, we constructed the wild-type (WT) and mutant Dvl-3 plasmids (myc-tagged) to evaluate the effect of different Dvl-3 domains (Fig. 4a). Coimmunoprecipitation results showed that Dvl-3 DEP domain contributed to the interaction of Wnt5b with Fzd3 and Dvl-3. After cotransfection with myc-Dvl-3 plasmid and GFP-Wnt5b, Wnt5b was able to interact with Fzd3 and Dvl-3. However, this interaction was abrogated upon the deletion of DEP domain, as well as the deletion of both of DEP and PDZ domains, but not the deletion of DIX or PDZ.
Next, we tested the effect of Dvl-3 domains on Wnt5b-mediated Dvl-3 phosphorylation. After cotransfection GFP-Wnt5b with myc-Dvl-3 plasmid, Wnt5b was able to promote the phosphorylation of Dvl-3 and JNK. However, this effect is significantly abrogated upon the deletion of Dvl-3 DEP domain, as well as the deletion of both of DEP and PDZ domains, but not the deletion of DIX or PDZ domain (Fig. 4c). Dvl-3 could activate JNK [13]. And we also found that JNK phosphorylation induced by Wnt5b mainly depended on Dvl-3 DEP domain (Fig. 4c).

JNK is important for Wnt/PCP signaling [15-17]. We found that Wnt5b-mediated ATF2 reporter activation also depended on Dvl-3 DEP domain, but not the PDZ/DIX domain (Fig. S7). And we also detected the effect of Dvl-3 mutation on the malignant phenotype of NSCLC cell induced by Wnt5b. The result showed that Wnt5b and Dvl-3 transfection promoted the cell invasiveness, colony formation, proliferation and migration. However, this effect was abrogated upon the deletion of DEP domain, as well as the deletion of both of DEP and PDZ domains, but not the PDZ or DIX domain (Fig. S8). Take together, Dvl-3 DEP domain is necessary for Wnt5b-mediated Dvl-3 phosphorylation and the subsequent activation of PCP/JNK signaling, as well as the malignant phenotype of NSCLC cell induced by Wnt5b.

Previous results confirmed that Fzd3 was important for Wnt5b induced Dvl-3 phosphorylation (Fig. 3d, e). To test the effect of Fzd3, we performed cell membrane protein and cytoplasmic protein extraction kit and immunofluorescence. The result confirmed that Wnt5b promoted Dvl-3 phosphorylation on the cell membrane.
adding siRNA-Fzd3, Dvl-3 phosphorylation was significantly decreased (Fig. 5a and Fig. S9). Immunofluorescent images showed that Dvl-3 membrane expression was abrogated upon the DEP domain deletion, as well as the deletion of both of the DEP and PDZ domains, but not the PDZ or DIX domain (Fig. 5b). Above results indicated that Dvl-3 DEP domain is necessary for Wnt5b-mediated Dvl-3 phosphorylation through Fzd3 on the cell membrane.

Dvl-3 DEP domain is necessary for Wnt5b-mediated Rac1 activation and the subsequent activation of PCP/JNK signaling

Wnt ligands transduce signals by activating Dvl, which can activate Rac1 [36], a member of Rho family of small GTPase, and then activate downstream JNK signaling [37, 38]. JNK activation is related to cancer progression. Our previous studies confirmed that Dvl-3 could activate JNK signaling in NSCLC [13]. Herein, we found that Dvl-3 transfection promoted Rac1 activation (Fig. S10a). Wnt5b significantly promoted the phosphorylation of Dvl-3 and JNK (Fig. 4c). Wnt5b resulted in Rac1 activation, but this effect was abrogated upon Fzd3 knockout (Fig. 6a and Fig. S10b). And cotransfection GFP-Wnt5b with myc-Dvl-3 promoted Rac1 activation, but this effect was abrogated upon the deletion of Dvl-3 DEP domain, as well as the deletion of both the DEP and PDZ domains, but not the PDZ or DIX domain (Fig. 6b). However, the effect of Wnt5b mediated cdc42 activation is not affected by any domain deletion (Fig. S10c). The effect of Wnt5b mediated JNK activation was significantly inhibited by adding Rac1 inhibitor, but this effect is not affected by
cdc42 inhibitor (Fig. 6c). Above results indicated that Dvl-3 DEP domain is necessary for Wnt5b mediated Rac1 activation and the subsequent activation of PCP/JNK signaling.

**Wnt5b is involved in PD-L1 induction through JNK**

JNK could upregulate PD-L1 expression in malignant tumors [18, 39]. So we explored whether Wnt5b regulated PD-L1 through JNK signaling.

Wnt5b significantly upregulated PD-L1 expression. JNK phosphorylation was increased upon Wnt5b. However, Wnt5b induced PD-L1 upregulation was inhibited by JNK inhibitor (Fig. 6d). It confirmed that JNK was important for Wnt5b induced PD-L1 upregulation.

We also evaluated the effect of PD-L1 antibody in vivo. After anti-mouse-PD-L1 antibody treatment, Wnt5b induced tumorigenesis was inhibited significantly (A549: Wnt5b+anti-PD-L1 versus Wnt5b+negative control; weight, 0.58±0.05 g versus 1.37±0.13 g; volume, 0.57±0.09 cm$^3$ versus 1.46±0.08 cm$^3$; P<0.05) (Fig. 6e, f).

**Discussion**

Noncanonical Wnt/PCP pathways regulate tumourigenesis. Wnt5b belongs to noncanonical Wnt ligand, which is involved in PCP pathway [4]. Herein, we demonstrated that Wnt5b overexpression was directly correlated with high TNM stage, lymph node metastasis, and poor prognosis of NSCLC patients. And Wnt5b enhanced the malignant phenotype of NSCLC in vivo and in vitro. So Wnt5b might be a
prognosis factor of NSCLC. Wnt5b is able to enhance Wnt/PCP signaling in NSCLC cells.

Wnt ligand binds to Fzd receptor and triggers signal cascade reaction in Wnt/PCP pathway [40-42]. Fzd4 regulates arterial formation and organization via Wnt/PCP signaling [43]. Fzd5 activates noncanonical Wnt pathway [44]. As a noncanonical Wnt ligand, Wnt5a binds to Fzd3 and activates downstream JNK pathway [45]. Fzd3 and Fzd6 control the polarity of developing skin via Wnt/PCP pathway [30]. The binding of Wnt5a to Fzd3 activates noncanonical Wnt signaling [46, 47]. Wnt5a and Wnt5b are the most similar in structure. Herein, we demonstrated that Wnt5b bound to Fzd3 in NSCLC cells, and Wnt5b promoted Wnt/PCP signaling via Fzd3 in NSCLC.

Dvl transduces different Wnt signals to downstream pathways via Fzd [28]. The PDZ and DIX domains of Dvl are important for both canonical and noncanonical Wnt pathways, whereas DEP domain acts on Wnt/PCP signaling [42, 48-49]. DEP domain could activate JNK signaling, which is important for Wnt/PCP pathway [50, 51]. And DEP domain is necessary for Dvl membrane localization; its deletion inhibits the Dvl membrane localization and impairs PCP signaling [42, 48-49, 52]. Wnt ligands transduce various signals to activate Dvl, which can activate downstream small GTPase Rac1 [36, 53], and then activate downstream JNK signaling [37]. Herein, we found that under the effect of Wnt5b ligand, Fzd3 receptor initiate Dvl-3 membrane recruitment via DEP domain and then activate PCP/JNK signaling via Rac1 in NSCLC cell.
Activated T-lymphocytes triggers tumor cell death, but tumor cells could avoid this immune process so as to proliferate, depending on the immune checkpoint pathway. As a T cell immune checkpoint, PD-1 mediates immunosuppression. PD-L1 is expressed on tumor cells [54]. The interaction between PD-1 and PD-L1 could inhibit T-cell responses and preclinical antitumor activity [55]. Therefore, the PD-L1 expression is a predictor of the response to immune checkpoint inhibitors and the survival of the patients [56]. JNK signaling contributes to the upregulation of PD-L1 expression in malignant tumors [18, 39]. Herein, Wnt5b and PD-L1 coexpression was significantly correlated with poor prognosis of NSCLC patients; Wnt5b upregulated PD-L1 through JNK signaling. And anti-mouse-PD-L1 antibody treatment inhibited Wnt5b induced tumorigenesis significantly. So we hypothesize that Wnt5b is involved in PD-L1 induction, in turn, influencing the immune response in human NSCLC.

Conclusion

Overall, Wnt5b and PD-L1 coexpression in NSCLC is significantly correlated with poor prognosis. And we propose a signal transduction pathway as illustrated in Fig. S11: Wnt5b might recruit Dvl-3 by DEP domain to the membrane via Fzd3 so as to promote Rac1–PCP/JNK signaling, leading to increased PD-L1 expression and the progression of NSCLC. This pathway may provide a novel insight for targeted therapy and immunotherapy of lung cancer patient.

Abbreviations
PD-L1: programmed-death ligand 1; NSCLC: non-small cell lung cancer; Fzd: Frizzled; SPF: specific pathogen-free; WT: wild-type; Dvl-3: Dishevelled-3; PCP: planar cell polarity; PD-1: programmed cell death protein 1; MAPK: mitogen-activated protein kinase; JNK: c-Jun N-terminal kinase; ATCC: American Type Culture Collection; AC: adenocarcinoma; SCC: squamous cell carcinoma.

Ethics approval and consent to participate

NSCLC tissue samples were obtained from the patients in the First Affiliated Hospital of China Medical University. Written informed consent was obtained from them. Work procedures were approved by the Institute Research Ethics Committee (No. 2016 [LS] 014, China Medical University). The animal experiments were conducted in accordance with the experimental animal ethics guidelines established by China Medical University. The Institutional Animal Research Committee of China Medical University approved this study.

Consent for publication

Not applicable

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the National Natural Science Foundation of China (No.81602022); and the National Training Program of Innovation and Entrepreneurship for Undergraduates of China Medical University in 2019 (No.201910159201).

Authors' contributions

Guangping Wu: Conceptualization, writing - review & editing; Yuan Luo: Data curation, software; Yusai Xie: Data curation, investigation; Yang Han: Methodology, validation; Di Zhang: Data curation, investigation; Qiang Han: Software, investigation; Xinran Zhao: Software, data curation; Ye Qin: Data curation, resources; Qingchang Li: Supervision, investigation; Enhua Wang: Conceptualization, writing - review & editing; Huanyu Zhao: Conceptualization, data curation, formal analysis, writing - review & editing. All authors read and approved the final manuscript.

Acknowledgements

We thank Dr. Weinan Li for his technical support.
References


283 pathway, respectively, and associate with poor prognosis in nonsmall cell lung cancer.
285 15. Gómez-Orte E, Sáenz-Narciso B, Moreno S, Cabello J. Multiple functions of the
288 MCAM coordinates apical-basal polarity and planar cell polarity during
290 17. Geetha-Loganathan P, Nimmagadda S, Fu K, Richman JM. Avian facial
291 morphogenesis is regulated by c-Jun N-terminal kinase/planar cell polarity (JNK/PCP)
294 upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and
297 requirement and subtype specificity in the high-affinity interaction between human
300 CK1ε and p120-catenin control Ror2 function in noncanonical Wnt signaling. Mol
303 al. The 2015 World Health Organization Classification of Lung Tumors: impact of


329 3 and frizzled 6 in planar cell polarity control of mouse hair follicles. Development.
330 2018;145:dev168468.
331 31. Mentink RA, Rella L, Radaszkiewicz TW, Gybel T, Betist MC, Bryja V, et al. The
332 planar cell polarity protein VANG-1/Vangl negatively regulates Wnt/β-catenin
334 32. Gammons MV, Rutherford TJ, Steinhart Z, Angers S, Bienz M. Essential role of
335 the Dishevelled DEP domain in a Wnt-dependent human-cell-based complementation
337 33. Jiang X, Charlat O, Zamponi R, Yang Y, Cong F. Dishevelled promotes Wnt
338 receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases. Mol
341 Suppression of planar cell polarity signaling and migration in glioblastoma by
344 Dishevelled enables casein kinase 1-mediated phosphorylation of Frizzled 6 required
346 36. Čajánek L, Ganji RS, Henriques-Oliveira C, Theofilopoulos S, Koník P, Bryja V,
347 et al. Tiam1 regulates the Wnt/Dvl/Rac1 signaling pathway and the differentiation of


44. Slater PG, Ramirez VT, Gonzalez-Billault C, Varela-Nallar L, Inestrosa NC. Frizzled-5 receptor is involved in neuronal polarity and morphogenesis of


**Figure legends**

**Fig. 1.** The expression of Wnt5b in NSCLC tissues and cell lines. (a) Wnt5b staining in normal bronchial epithelial cells, alveolar epithelial cells, squamous cell carcinoma (SCC) and adenocarcinoma (AC); PD-L1 staining in SCC and AC (magnification: ×400; scale bar, 20 µm). (b) Quantification of Wnt5b mRNA levels in human NSCLC...
specimens and paired normal lung tissues by real-time PCR. (c) Wnt5b protein expression in five NSCLC cell lines and the normal bronchial cell line HBE. (d) The survival time of patients with Wnt5b-negative staining (I) and Wnt5b-positive staining (II). (e) The survival time of patients without Wnt5b and PD-L1 coexpression (I) and that of patients with coexpression (II). *, P<0.05.

Fig. 2. The influence of Wnt5b on the biological behavior of NSCLC cells. Colony formation (a, b), invasiveness (c, d), proliferation (e, f) and migration (g, h) of A549 and SPC cells; CTL, control, empty vector, the control group of Wnt5b expression plasmid. siWnt5b: siRNA-Wnt5b. siCTL, siRNA-control selected as a negative control. (i-n) Subcutaneously injected tumours (G418 screening, n=5). (o-r) Intravenously injection tumours (G418 screening, n=5). The arrow points to the cancerous area. Columns: mean numbers. shWnt5b, shRNA-Wnt5b. shNC, shRNA-negative control. *, P<0.05.

Fig. 3. The impact of Wnt5b on the Wnt/PCP pathway. (a) Dual-luciferase assay analyses of Wnt/PCP signaling. Transfection of siRNA-Wnt5b (siWnt5b) or Wnt5b expression plasmid (Wnt5b) to NSCLC cells. ATF2 luciferase was used to measure Wnt/PCP activity, and the values of luciferase activities were normalized with renilla activity. (b) Western blot analyses of target proteins; transfection of siWnt5b or Wnt5b to NSCLC cells; p-Dvl-1, Dvl-1 phosphorylation; p-Dvl-3, Dvl-3 phosphorylation. (c) Coimmunoprecipitation analyses of endogenous interaction
between Wnt5b, Fzd and Dvl-3 in A549. (d) Western blot analyses of Dvl-3 phosphorylation. (e) Dual-luciferase assay analyses of Wnt/PCP signaling; cotransfection of siRNA-Fzd3 (siFzd3) with GFP-Wnt5b. (f-g) Coimmunoprecipitation analyses of endogenous interaction between Wnt5b, Fzd3 and Dvl-3 in A549 and SPC. (h) Coimmunoprecipitation analyses of the interaction of Wnt5b with Dvl-3 in A549; cotransfection of siFzd3 with GFP-Wnt5b and myc-Dvl-3 plasmids. β-actin or GAPDH was selected as a control. siCTL, siRNA-control. *, P <0.05.

Fig. 4. Wnt5b interacted with Dvl-3 DEP domain to promote Dvl-3 phosphorylation and JNK activation. (a) The WT Dvl-3 plasmid and mutant Dvl-3 plasmids (∆: this domain deletion). (b) Coimmunoprecipitation analyses of the interaction of Wnt5b with Fzd3 and Dvl-3; the resultant cell lysates were immunoprecipitated with GFP/myc/Fzd3 antibody; the presence of Wnt5b/Dvl-3/Fzd3 was confirmed by anti-GFP/myc/Fzd3 immunoblotting. (c) Western blot analyses of Dvl-3 and JNK. Cotransfection of GFP-Wnt5b with WT myc-Dvl-3 or Dvl-3 mutant plasmids to A549 cell; p-Dvl-3, Dvl-3 phosphorylation; p-JNK, JNK phosphorylation. β-actin was selected as a negative control. ∆DE+PD: ∆DEP+PDZ.

Fig. 5. The effect of Wnt5b on Dvl-3 membrane recruitment. (a) Western blot analyses of Dvl-3 phosphorylation on cell membrane and cytoplasm; cotransfection of siRNA-Fzd3 (siFzd3) with Wnt5b expression plasmid (Wnt5b) to A549 or
siRNA-Wnt5b (siWnt5b) with Wnt5b to SPC for 48 h. CTL, control, empty vector, the control group of Wnt5b expression plasmid; siCTL, siRNA-control. p-Dvl-3, Dvl-3 phosphorylation. Na-K ATPase was a reference control for membrane. (b) Analysis of Dvl-3 localization with confocal microscopy (magnification: ×400); cotransfection of GFP-Wnt5b with WT myc-Dvl-3 or Dvl-3 mutant plasmids for 48 h to A549 cell.

Fig. 6. The impact of Wnt5b on Rac1, JNK and PD-L1. (a) Western blot analyses of activated Rac1; cotransfection of siRNA-Fzd3 (siFzd3) with Wnt5b expression plasmid (Wnt5b) or siRNA-Wnt5b (siWnt5b). (b) Western blot analyses of Rac1 in A549 cell; cotransfection of GFP-Wnt5b with WT myc-Dvl-3 or Dvl-3 mutant plasmids. (c) Western blot analyses of Rac1, cdc42 and JNK. P-JNK, JNK phosphorylation; transfection of GFP-Wnt5b (Wnt5b) to A549 cell. After Wnt5b transfection, NSC23766 (a Rac1 inhibitor, 100 μM, Wnt5b+NSC) or ML141 (a cdc42 inhibitor, 10 μM, Wnt5b+ML141) was treated for 24 h. Whole-cell lysates were run on parallel gels to determine total Rac1 or cdc42. (d) Western blot analyses of PD-L1 and JNK; transfection of GFP-Wnt5b (Wnt5b) to A549. After Wnt5b transfection, SP600125 (JNK inhibitor, 10 μM, Wnt5b+SP) was treated for 24 h. (e-g) Subcutaneously injected tumours of A549 cell stably expressing Wnt5b (G418 screening, n=5) with PD-L1 antibody treatment. CTL, control, empty vector, the control group of Wnt5b expression plasmid; siCTL, siRNA-control. β-actin was
selected as a negative control. W+N, Wnt5b+negative control for PD-L1 antibody; W+P, Wnt5b+PD-L1 antibody. *, P <0.05.
The expression of Wnt5b in NSCLC tissues and cell lines. (a) Wnt5b staining in normal bronchial epithelial cells, alveolar epithelial cells, squamous cell carcinoma (SCC) and adenocarcinoma (AC); PD-L1 staining in SCC and AC (magnification: ×400; scale bar, 20 µm). (b) Quantification of Wnt5b mRNA levels in human NSCLC specimens and paired normal lung tissues by real-time PCR. (c) Wnt5b protein expression in five NSCLC cell lines and the normal bronchial cell line HBE. (d) The survival time of patients with Wnt5b-negative staining (I) and Wnt5b-positive staining (II). (e) The survival time of patients without Wnt5b and PD-L1 coexpression (I) and that of patients with coexpression (II). *, P<0.05.
Figure 2

The influence of Wnt5b on the biological behavior of NSCLC cells. Colony formation (a, b), invasiveness (c, d), proliferation (e, f) and migration (g, h) of A549 and SPC cells; CTL, control, empty vector, the control group of Wnt5b expression plasmid. siWnt5b: siRNA-Wnt5b. siCTL, siRNA-control selected as a negative control. (i-n) Subcutaneously injected tumours (G418 screening, n=5). (o-r) Intravenously injection
The impact of Wnt5b on the Wnt/PCP pathway. (a) Dual-luciferase assay analyses of Wnt/PCP signaling. Transfection of siRNA-Wnt5b (siWnt5b) or Wnt5b expression plasmid (Wnt5b) to NSCLC cells. ATF2 luciferase was used to measure Wnt/PCP activity, and the values of luciferase activities were normalized.
with renilla activity. (b) Western blot analyses of target proteins; transfection of siWnt5b or Wnt5b to NSCLC cells; p-Dvl-1, Dvl-1 phosphorylation; p-Dvl-3, Dvl-3 phosphorylation. (c) Coimmunoprecipitation analyses of endogenous interaction between Wnt5b, Fzd and Dvl-3 in A549. (d) Western blot analyses of Dvl-3 phosphorylation. (e) Dual-luciferase assay analyses of Wnt/PCP signaling; cotransfection of siRNA-Fzd3 (siFzd3) with GFP-Wnt5b. (f-g) Coimmunoprecipitation analyses of endogenous interaction between Wnt5b, Fzd3 and Dvl-3 in A549 and SPC. (h) Coimmunoprecipitation analyses of the interaction of Wnt5b with Dvl-3 in A549; cotransfection of siFzd3 with GFP-Wnt5b and myc-Dvl-3 plasmids. β-actin or GAPDH was selected as a control. siCTL, siRNA-control. *, P <0.05.
Wnt5b interacted with Dvl-3 DEP domain to promote Dvl-3 phosphorylation and JNK activation. (a) The WT Dvl-3 plasmid and mutant Dvl-3 plasmids (Δ: this domain deletion). (b) Coimmunoprecipitation analyses of the interaction of Wnt5b with Fzd3 and Dvl-3; the resultant cell lysates were immunoprecipitated with GFP/myc/Fzd3 antibody; the presence of Wnt5b/Dvl-3/Fzd3 was confirmed by anti-GFP/myc/Fzd3 immunoblotting. (c) Western blot analyses of Dvl-3 and JNK. Cotransfection of GFP-Wnt5b with WT myc-Dvl-3 or Dvl-3 mutant plasmids to A549 cell; p-Dvl-3, Dvl-3 phosphorylation; p-JNK, JNK phosphorylation. β-actin was selected as a negative control. ΔDE+PD: ΔDEP+PDZ.
The effect of Wnt5b on Dvl-3 membrane recruitment. (a) Western blot analyses of Dvl-3 phosphorylation on cell membrane and cytoplasm; cotransfection of siRNA-Fzd3 (siFzd3) with Wnt5b expression plasmid (Wnt5b) to A549 or siRNA-Wnt5b (siWnt5b) with Wnt5b to SPC for 48 h. CTL, control, empty vector, the control group of Wnt5b expression plasmid; siCTL, siRNA-control. p-Dvl-3, Dvl-3 phosphorylation. Na-K ATPase was a reference control for membrane. (b) Analysis of Dvl-3 localization with confocal microscopy (magnification: ×400); cotransfection of GFP-Wnt5b with WT myc-Dvl-3 or Dvl-3 mutant plasmids for 48 h to A549 cell.
Figure 6

The impact of Wnt5b on Rac1, JNK and PD-L1. (a) Western blot analyses of activated Rac1; cotransfection of siRNA-Fzd3 (siFzd3) with Wnt5b expression plasmid (Wnt5b) or siRNA-Wnt5b (siWnt5b). (b) Western blot analyses of Rac1 in A549 cell; cotransfection of GFP-Wnt5b with WT myc-Dvl-3 or Dvl-3 mutant plasmids. (c) Western blot analyses of Rac1, cdc42 and JNK. P-JNK, JNK phosphorylation; transfection of GFP-Wnt5b (Wnt5b) to A549 cell. After Wnt5b transfection, NSC23766 (a Rac1 inhibitor, 100 μM, Wnt5b+NSC) or ML141 (a cdc42 inhibitor, 10 μM, Wnt5b+ML141) was treated for 24 h. Whole-cell lysates were run on parallel gels to determine total Rac1 or cdc42. (d) Western blot analyses of PD-L1 and JNK; transfection of GFP-Wnt5b (Wnt5b) to A549. After Wnt5b transfection, SP600125 (JNK inhibitor, 10 μM, Wnt5b+SP) was treated for 24 h. (e-g) Subcutaneously injected tumours of A549 cell stably expressing Wnt5b (G418 screening, n=5) with PD-L1 antibody treatment. CTL, control, empty vector, the control group of Wnt5b expression plasmid; siCTL, siRNA-control. β-actin was selected as a negative control. W+N, Wnt5b+negative control for PD-L1 antibody; W+P, Wnt5b+PD-L1 antibody. *, P <0.05.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile13Fig.S11.pdf
- Additionalfile13Fig.S11.pdf
- Additionalfile12Fig.S10.pdf
- Additionalfile12Fig.S10.pdf
- Additionalfile11Fig.S9.pdf
- Additionalfile11Fig.S9.pdf
- Additionalfile10Fig.S8.pdf
- Additionalfile10Fig.S8.pdf
- Additionalfile9Fig.S7.pdf
- Additionalfile9Fig.S7.pdf
- Additionalfile8Fig.S6.pdf
- Additionalfile8Fig.S6.pdf
- Additionalfile7Fig.S5.pdf
- Additionalfile7Fig.S5.pdf
- Additionalfile6Fig.S4.pdf
- Additionalfile6Fig.S4.pdf
- Additionalfile5Fig.S3.pdf
- Additionalfile5Fig.S3.pdf
- Additionalfile4Fig.S2.pdf
- Additionalfile4Fig.S2.pdf
- Additionalfile3Fig.S1.pdf
- Additionalfile3Fig.S1.pdf
- Additionalfile2TableS2.doc
- Additionalfile2TableS2.doc
- Additionalfile1TableS1.doc
- Additionalfile1TableS1.doc
- Supplementaryfiles.doc
- Supplementaryfiles.doc